Abbott Laboratories (ABT) EVP and Group President reports 1,536-share stock transaction

Rhea-AI Filing Summary

Abbott Laboratories executive reports equity transaction in company stock. A reporting person serving as EVP and Group President of Abbott Laboratories (ticker ABT) filed a Form 4 covering activity on 12/11/2025. The filing shows a transaction in Abbott common shares without par value, coded "G" under the transaction code and marked as a disposition of 1,536 shares at a price of $123.28 per share.

Following this transaction, the reporting person is shown as beneficially owning 132,233 Abbott common shares in direct ownership form. The filing is made as an individual Form 4 for one reporting person and is signed by an attorney-in-fact on 12/12/2025.

Insider Trade Summary

1,536 shares gifted

Mixed 1 txn

Insider Salvadori Daniel Gesua Sive

Role EVP AND GROUP PRESIDENT

Type	Security	Shares	Price	Value
Gift	Common shares without par value	1,536	$123.28	$189K

Holdings After Transaction: Common shares without par value — 132,233 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Salvadori Daniel Gesua Sive

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP AND GROUP PRESIDENT

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	12/11/2025		G		1,536	D	$123.28	132,233	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Abbott Laboratories (ABT) report on this Form 4?

The Form 4 reports a transaction in Abbott Laboratories common shares without par value on 12/11/2025, coded "G" as a disposition of 1,536 shares.

At what price were the Abbott Laboratories (ABT) shares transacted?

The reported transaction shows 1,536 Abbott common shares disposed of at a price of $123.28 per share.

How many Abbott Laboratories (ABT) shares does the insider own after the transaction?

After the reported transaction, the insider is shown as beneficially owning 132,233 Abbott common shares, held in direct ownership form.

What is the role of the reporting person at Abbott Laboratories (ABT)?

The reporting person is identified as an Officer of Abbott Laboratories, with the title EVP AND GROUP PRESIDENT.

Is this Abbott Laboratories (ABT) Form 4 filed by more than one reporting person?

No. The Form 4 indicates it is a Form filed by One Reporting Person, not a joint or group filing.

When was this Abbott Laboratories (ABT) Form 4 signed?

The Form 4 is signed "/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact" and dated 12/12/2025.